TCF3 ChIP-Seq in BL cell lines
Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics
ChIP-Seq of TCF3 factor using antibody against TCF3 or biotag in Namalwa and BL41 cell line.
Burkitt lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries, necessitating new strategies.  We used high throughput RNA sequencing and RNA interference screening to discover essential regulatory pathways that cooperate with MYC, the defining oncogene of this cancer.  In 38% of sporadic BL (sBL) cases, oncogenic CCND3 mutations produced highly stable cyclin D3 isoforms that drive cell cycle progression.  In 70% of sBL cases, mutations affecting the transcription factor TCF3 or its negative regulator ID3 fostered TCF3 dependency.  TCF3 activated the pro-survival PI(3) kinase pathway in BL, in part by augmenting constitutive B cell receptor signaling.  These findings suggest opportunities to improve therapy for patients with BL.